Pharmaceutical compounds

ABSTRACT

A pharmaceutical compound of the formula: ##STR1## in which n is 1 or 2, R 1  is --CO 2  H, R 2  is hydrogen or C 1-4  alkyl and 
     R 3  is hydrogen, C 1-10  alkyl, C 2-10  alkenyl, optionally substituted phenyl, optionally substituted phenyl-C 1-4  alkyl, optionally substituted phenyl C 2-10  alkenyl,(optionally substituted phenyl) 2  -C 1-4  alkyl, optionally substituted C 3-7  cycloalkyl, optionally substituted C 3-7  cycloalkyl-C 1-4  alkyl or optionally substituted C 3-7  cycloalkyl-C 2-10  alkenyl, or 
     R 2  and R 3 , together with the carbon atom to which they are attached, form an optionally substituted C 4-7  cycloalkyl group; 
     or a salt or ester thereof other than the compounds γ-propylidene-L-glutamic acid, γ-ethylidene-L-glutamic acid and γ-methylidene-L-glutamic acid.

This invention relates to novel chemical compounds and their use as pharmaceuticals.

It is well known that excitatory neurotransmission in the mammalian central nervous system is primarily mediated by the amino acid, L-glutamate, acting on ionotropic and metabotropic receptors, and compounds that modify neurotransmission by interaction with these receptors are of interest for their potential use in the treatment of disorders of the central nervous system.

JP 78043519 (Mitsubishi Kasei Kogyo K. K.)discloses the isolation from a fungus of the non-protein amino acids γ-propylidene-L-glutamic acid, γ-ethylidene-L-glutamic acid and γ-methylidene-L-glutamic acid. The activity of the latter compound and some analogs towards glutamate receptors is described in Synlett (June 1993) p 409.

The compounds of the invention have the general formula: ##STR2##

in which n is 1 or 2, R¹ is --CO₂ H,

R² is hydrogen or C₁₋₄ alkyl and

R³ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₄ alkyl, optionally substituted phenyl C₂₋₁₀ alkenyl,(optionally substituted phenyl)₂ -C₁₋₄ alkyl, optionally substituted C₃₋₇ cycloalkyl, optionally substituted C₃₋₇ cycloalkyl-C₁₋₄ alkyl or optionally substituted C₃₋₇ cycloalkyl-C₂₋₁₀ alkenyl, or

R² and R³, together with the carbon atom to which they are attached, form an optionally substituted C₄₋₇ cycloalkyl group;

or a salt or ester thereof other than the compounds γ-propylidene-L-glutamic acid, γ-ethylidene-L-glutamic acid and γ-methylidene-L-glutamic acid.

The compounds of the invention have been found to be active in tests indicative of their use in the treatment of diseases of the central nervous system such as neurological diseases, for example, neurodegenerative diseases, and as antipsychotic, anticonvulsant, analgesic and anti-emetic agents.

In the above general formula, a C₁₋₁₀ alkyl group can be straight or branched chain, such as, for example, methyl, ethyl, propyl, isopropyl, butyl and isobutyl,. A C₂₋₁₀ alkenyl group includes, for example, vinyl, prop-2-enyl, but-3-enyl, pent-4-enyl and isopropenyl, and an alkenyl group can contain more than one double bond and, in addition, one or more triple bonds. A preferred alkenyl group is of the formula R'--CH═CH-- where R' is C₁₋₄ alkyl.

A c₃₋₁₀ cycloalkyl group is preferably, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and these groups may optionally be substituted by one or two C₁₋₄ alkyl, for example methyl, substituents, or can be a bicyclo-system as, for example, bicyclooctane or adamantyl.

In the above general formula, a phenyl group is optionally substituted with, for example, one or more substituents selected from C₁₋₄ alkyl, especially methyl, C₁₋₄ alkoxy, especially methoxy and ethoxy, carboxy, hydroxy, cyano, halo, especially bromo, chloro and fluoro, trifluoromethyl, nitro, amino (including alkyl substituted amino), C₁₋₄ acylamino and C₁₋₄ alkylthio. When substituted, a phenyl is preferably substituted by one to three substituents. It is preferred that n is 1.

A preferred group of compounds according to formula (I) is one in which n is 1, R¹ is --CO₂ H, R² is hydrogen and R³ is C₃₋₄ alkyl,or branched alkyls such as isopropyl or R² and R³ together with the carbon atom to which they are attached form an optionally substituted C₄ or C₅ cycloalkyl.

A preferred subgroup is one in which R² is hydrogen and R³ is C₁₋₄ alkyl.

Particularly preferred compounds are

(2S,E,E)-2-Amino-4-(p-nitrocinnamylidene)pentanedioic acid

(2S,E,E)-2-Amino-4-(p-dimethylaminocinnamylidene)pentanedioic acid

(2S,E,E)-2-Amino-4-cinnamylidenepentanedioic acid

(2S,E)-2-Amino-4-pentylidenepentanedioic acid

(2S)-2-Amino-4-isopropylidenepentanedioic acid

(2S)-2-Amino-4-cyclobutylidenepentanedioic acid

(2S,E)-2-Amino-4-(p-chlorophenylmethylidene)pentanedioic acid

(2S)-2-Amino-4-cyclohexylidenepentanedioic acid

(2S,E)-2-Amino-4-cyclopentylmethylidenepentanedioic acid and

(2S)-2-Amino-4-cyclopentylidenedioic acid.

It will also be understood that salts of the compounds of the invention can be prepared and such salts are included in the invention. They can be any of the well known base or acid addition salts. Examples of base salts are those derived from ammonium hydroxide and alkali and alkaline earth metal hydroxides, carbonates and bicarbonates, as well as salts derived from aliphatic and aromatic amines, aliphatic diamines and hydroxy alkylamines. Bases especially useful in the preparation of such salts include ammonium hydroxide, potassium carbonate, sodium bicarbonate, lithium hydroxide, calcium hydroxide, methylamine, diethylamine, ethylene diamine, cyclohexylamine and ethanolamine. The potassium and sodium salt forms are particularly preferred.

Acid addition salts are preferably the pharmaceutically-acceptable, non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example glycollic, maleic, fumaric, malic, tartaric, citric, salicylic or o-acetoxybenzoic acids, or organic sulphonic acids, methane sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic or naphthalene-2-sulphonic acids.

In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically-acceptable, salts, or are useful for identification, characterisation or purification.

The compounds can also be utilised in ester form, such esters being aliphatic or aromatic, such as, for example, alkyl and phenolic esters. The most preferred esters are alkyl esters derived from C₁₋₄ alkanols, especially methyl and ethyl esters.

It will be appreciated that the compounds of the invention contain an asymmetric carbon atom as indicated by the asterisk in formula (I), and this gives rise to enantiomers. The preferred stereochemistry for the compunds is the 2S enantiomer. The compounds can be prepared as racemates or as enantiomers, and individual enantiomers can be isolated from racemates by conventional techniques if so desired. Such racemates and individual enantiomers form part of the present invention.

It will also be appreciated that the compounds of the invention contain a double bond and this gives rise to geometric isomers (E, Z), both of which are included in the invention.

The invention also includes a process for the production of compounds of the invention, which comprises hydrolysing a compound of the formula: ##STR3##

where R⁴ and R⁵ are each carboxy protecting groups, to give a compound of formula (I).

The reaction described in process variant (1) is one of hydrolysis under conventional hydrolysis conditions using acid and/or base. Hydrolysis results in the opening up of the cyclic structure, and the loss of protecting groups. Preferably the reaction is carried out at room temperature, in an organic solvent such as, for example tetrahydrofuran with, for example, aqueous lithium hydroxide. Removal of protecting groups can be carried out with, for example, saturated hydrochloric acid in ethyl acetate.

Novel intermediate compounds of formula (II) are included as part of the present invention and can be prepared by the action of base on a mesylate derivative of formula: ##STR4## where Ms is mesylate, which leads to the formation of the unsaturated side-chain (it would be understood that other leaving groups such as tosylate, brosylate and halogens, would also be suitable). Compounds of formula (III) are prepared by mesylation of the corresponding hydroxy compound formed by reaction of the appropriate ketone or aldehyde of the formula R² COR³, with the pyroglutamate derivative of the formula: ##STR5## in the presence of strong base such as lithium hexamethyldisilazide, which facilitates the reaction with the ring carbon atom.

According to a further aspect of the invention the compounds described above have pharmaceutical activity. They have been shown to possess affinity for glutamate receptors.

Excitatory amino acid or glutamate receptors are subdivided into two types, ionotropic and metabotropic. lonotropic glutamate receptors are intrinsic ligand gated ion channels that are composed of multiple subunit proteins forming multimeric complexes. Ionotropic glutamate receptors are selectively activated by the agonists N-methyl-D-asparate, AMPA, and kainate (Sommer B. And Seeburg P. H., Trends Pharmacol. Sci. 13: 291-296, 1993). Metabotropic glutamate receptors are a family of G-protein coupled receptors with novel molecular structure that are coupled to increases in phosphoinositide hydrolysis and decreases in cAMP formation. (Schoepp D. D. And Conn J. P., Trends Pharmacol. Sci. 14: 13-20, 1993).

The affinity of the compounds for ionotropic glutamate receptors has been demonstrated by binding assays in which cell membranes are incubated in the presence of radio-ligand[³ H]kainate and test compounds prior to separation by centrifugation (see U.S. Pat. No. 5,547,855). The compounds of the present invention are selective agonists of the iGluR5 kainate subreceptor with Ki values of less than 1000 μM.

The compounds of the invention are thus indicated for use in the treatment of neurological disorders such as acute neurodegenerative diseases, for example stroke, cerebral ischemia and head and spinal cord trauma, and chronic neurodegenerative diseases such as, for example, Alzheimer's disease, Parkinson's disease, Amyotropic lateral sclerosis, AIDS-induced dementia and Huntington's Chorea. The compounds are also indicated for use as antipsychotic, anticonvulsant, analgesic and anti-emetic agents. They are also of potential use as anxiolytic and antidepressant agents.

The invention also includes a pharmaceutical composition comprising a pharmaceutically-acceptable diluent or carrier in association with a compound of formula (I), or a pharmaceutically-acceptable salt thereof.

The compounds may be administered by various routes, for example, by the oral or rectal route, topically or parenterally, for example by injection, and are usually employed in the form of a pharmaceutical composition. Such compositions form part of the present invention and are prepared in a manner well known in the pharmaceutical art and normally comprise at least one active compound in association with a pharmaceutically-acceptable diluent or carrier. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, and/or enclosed with a carrier which may, for example, be in the form of a capsule, sachet, paper or other container. Where the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, as a solid or in a liquid medium, ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.

Some examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydroxbenzoate, talc, magnesium stearate and mineral oil. Compositions in injectable form may, as it is well known in the art, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.

When the compositions are formulated in unit dosage form, it is preferred that each unit dosage form contains from 5 mg to 500 mg, for example, from 15 mg to 200 mg. The term `unit dosage form` refers to physically discrete units suitable as unit dosages for human subjects and animals. Each unit contains a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.

The active compounds are effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.5 to 300 mg/kg, more usually in the range of from 5 to 100 mg/kg. However, it will be understood that the amount administered will be determined by the physician in the light of the relevant circumstances, including the condition to be treated, the choice of compound to be administered and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.

The invention is illustrated by the following Examples.

EXAMPLE 1

Procedure A

General procedure for aldol reactions on ethyl N-Boc pyroglutamate and further treatment of the resulting aldols mixtures with methanesulfonyl chloride and triethylamine. Synthesis of 4-alkylidene pyroglutamates.

To a solution of ethyl N-Boc pyroglutamate (15.6 mmol) in THF (50 mL) stirred at -78° C. was added a 1M solution of lithium hexamethyldisilazide in THF (18.7 mL, 18.7 mmol, 1.1 equiv). The reaction mixture was stirred for 1 hour at -78° C. prior to the addition of a solution of the aldehyde (17.2 mmol) and BF₃ OEt₂ (17.2 mmol) in THF (50 mL). The reaction mixture was stirred for 1 hour at -78° C. and then quenched with saturated ammonium chloride solution (100 mL) and extracted with ethyl ether (3×50 mL). The combined organic phases were dried over Na₂ SO₄, filtered and evaporated to dryness. The reaction crude was dissolved in CH₂ Cl₂ (30 mL) and treated with methanesulfonyl chloride (1.34 mL, 17.2 mmol) and triethylamine (18 mL, 172 mmol). After stirring this solution for three days at room temperature it was quenched with water and extracted with dichloromethane (3×50 mL). The organic layer was dried over Na₂ SO₄ and evaporated under reduced pressure affording the title compounds as mixtures of E/Z isomers. The eluent is indicated in the cases where chromatographic separation was carried out.

Ethyl (2S, E)-1-(tert-butoxycarbonyl)-4-anthrylmethylidenepyroglutamate

Only the E isomer was obtained. Yellow solid. m.p.: 62-3° C. (Hexane/ethyl acetate 3:1). [α]_(D) =+10.6° (c 0.6, CHCl₃). IR (KBr pellet) 2975, 1780, 1740, 1310, 1145 cm⁻¹. ¹ HNMR (CDCl₃) d 8.47 (S, 1H), 8.44 (t, J=3.1 Hz, 1H), 8.07-8.02 (m, 2H), 7.94-7.88 (m, 2H), 7.54-7.45 (m, 4H), 4.59 (dd, J=3.1 and 10.0 Hz, 1H), 4.20-4.07 (m, 2H), 2.76 (ddd, J=3.1, 10.0 and 18.0 Hz, 1H), 2.28 (dt, J=3.1 and 18.0 Hz, 1H), 1.57 (s, 9H), 1.20 (t, J=7.0 Hz, 3H). ¹³ C NMR (CDCl₃) d 170.8, 165.6, 149.8, 134.0, 138.2, 131.0, 128.9 (3C), 128.4 (2C), 127.8 (2C), 126.2 (2C), 125.3 (2C), 124.9 (2C), 83.6, 61.5, 55.8, 27.8 (3C), 27.1, 13.9. HRMS calcd for C₂₇ H₂₇ NO₅ : 445.1889, found 445.1887.

(2S, E)-1-(tert-Butoxycarbonyl)-4-(4,4-diphenylbutylidene) pyroglutamate ethyl ester

(hexane/ethyl acetate 4:1).

Colourless oil. [α]_(D) =+3.4° (c 1.0, CHCl₃). ¹ H NMR (CDCl₃). d 7.40-7.05 (m, 10H), 6.73 (tt, J=2.8 and 7.4 Hz, 1H), 4.51 (dd, J=3.6 and 10.3 Hz, 1H), 4.19 (q, J=7.1 Hz, 2H), 3.85 (t, J=7.7 Hz, 1H), 2.82-2.58 (m, 1H), 2.42-2.00 (m, 5H), 1.49 (S, 9H), 1.25 (t, J=7.1 Hz, 3H). ¹³ C NMR (CDCl₃) d 170.6, 165.3, 149.3, 143.6, 143.5, 137.8, 128.0 (2C), 127.2 (2C), 127.1 (2C), 125.8, 82.7, 61.0, 55.2, 53.1, 49.8, 33.2, 27.3, 27.0, 24.7, 13.6. IR (film) 1784, 1748, 1717, 1317, 1155 cm⁻¹.

(2S, Z)-1-(tert-Butoxycarbonyl)-4-(4,4-diphenylbutylidene) pyroglutamate ethyl ester

(hexane/ethyl acetate 4:1).

Colourless oil. [α]_(D) =-14.0° (c 1.0, CHCl₃). ¹ H NMR (CDCl₃) d 7.38-7.05 (m, 10H), 5.94 (m, 1H), 4.46 (dd, J=3.4 and 10.0 Hz, 1H), 4.16 (q, J=7.1 Hz, 2H), 3.92 (t, J=7.7 Hz, 1H), 2.95-2.63 (m, 3H), 2.45 (m, 1H), 2.14 (q, J=7.7 Hz, 2H), 1.48 (S, 9H), 1.21 (t, J=7.1 Hz, 3H). ¹³ C NMR (CDCl₃) d 170.8, 165.2, 149.6, 144.3, 144.2, 142.5, 128.0, 127.5 (2C), 127.4 (2C), 126.2, 125.7, 82.8, 61.1, 55.4, 50.8, 34.7, 28.6, 27.5, 25.6, 13.7. IR (film) 1784, 1747, 1717, 1323, 1155 cm⁻¹.

Ethyl (2S)-1-(tert-butoxycarbonyl)-4-(4-chlorobenzylidene) pyroglutamate

white solid. P.f.: 114-118° C. [a]_(D) ²⁰ : 6.2.

¹ H-RMN (CDCl₃): 7.37 (m, 1H, C═CH); 7.14 (m, 4H, Ar-H); 4.59 (dd, 1H, J=9.7 y 3.2 Hz, H-γ); 4.09 (c, 2H, J=7.0 Hz, CH₂ -Et); 3.21 (ddd, J=17.7, 10.2 y 2.7 Hz, H-β); 2.81 (dm, 1H, J=17.7, H-β); 1.41 (s, 9H, CH₃ -Boc); 1.15 (t, 3H, J=7.0 Hz, CH₃ -Et). ¹³ C-RMN (CDCl₃): 171.0 y 166.6 (CON y CO₂ Et); 149.8 (NCO₂ ^(t) Bu); 133.1, 128.6 y 127.8 (C); 133.8, 131.2 y 129.2 (CH); 127.8 (ArC-Cl); 83.8 (C-Boc); 61.9 (CH₂ -Et); 56.1 (C-γ); 27.9(CH₃ -Boc); 14.1 (CH₃ -Et). IR (cm⁻¹): 1775 y 1745 (st, C═O); 1660 (st, C═C); 1385 y 1375 (d, CH₃ -Boc); 835 y 775 (d, ArC-H). MS: 379 (0.4, M⁺); 297 (30); 208 (44); 206 (100); 178 (10); 56 (47).

Ethyl (2S)-1-(tert-butoxycarbonyl)-4-cyclopentylmethylidenepyroglutamate

Colourless oil ¹ H-RMN (CDCl₃): 6.63 (dt, 1H, J=10.0 y 2.0 Hz, CH═C); 4.56 (dd, 1H, J=10.0 y 3.2 Hz, H-γ); 4.19 (c, 2H, J=7.0 Hz, CH₂ -Et); 2.96 (ddd, 1H, J=16.4, 10.0 y 3.2 Hz, H-β); 2.50 (m, 2H, H-β y CH-Cp); 1.90-1.20 (m, 8H, CH₂); 1.55 (s, 9H, CH₃ -Boc); 1.25 (t, 3H, J=7.0 Hz, CH₃ -Et). IR (cm⁻¹): 1775 y 1730 (st, C═O); 1670 (st, C═C); 1390 y 1370 (d, CH₃ -Boc). MS: 237 (34); 186 (9); 164 (100); 96 (11); 81 (34); 57 (39).

Ethyl (2S)-1-(tert-butoxycarbonyl)-4-cyclohexylidenepyroglutamate

yellow oil. Isomer A: ¹ H-RMN (CDCl₃): 4.48 (dd, 1H, J=10.0 y 3.6 Hz, H-γ); 4.16 (c, 2H, J=7.0 Hz, CH₂ -Et); 2.95 (m, 1H, H-β) ; 2.55 (dd, 1H, J=15.4 y 3.6 Hz, H-β); 2.10 (m, 4H, CH₂); 2.00-1.1 (m, 6H, CH₂); 1.5 (s, 9H, CH₃ -Boc); 1.23 (t, 3H, J=7.0 Hz, CH₃ -Et). Isomer B: ¹ H-RMN (CDCl₃): 5.57 (m, 1H, CH═C); 4.54 (dd, 1H, J=8.9 y 2.3 Hz, H-γ); 4.19 (c, 2H, J=7.0 Hz, CH₂ -Et); 3.19 (dd, 1H, J=10.2 y 8.9 Hz, H-β); 2.95 (m, 1H, H-β); 2.10 (m, 5H, H-a y CH₂); 2.00-1.10 (m, 4H, CH₂); 1.55 (s, 9H, CH₃ -Boc); 1.25 (t, 3H, J=7.0 Hz, CH₃ -Et). ¹³ C-RMN (CDCl₃): 171.4 y 171.2 (CON, CO₂ Et); 157.2 (NCO₂ ^(t) Bu); 132.5 (C-a Iso A); 126.7 (CH═C Iso B); 125.4 (C-4 Iso B); 118.0 (C-4 Iso B); 83.0 (C-Boc); 61.4 y 61.3 (CH₂ -Et); 56.8 (C-γ); 49.7 (C-a Iso B ; 27.7 (CH₃ -Boc); 33.7, 28.1, 27.0, 26.0, 25.5, 25.1, 22.4, 21.9 (CH₂); 14.0 (CH₃ -Et). IR (Cm⁻¹): 1770 y 1720 (st, C═O); 1640 (st, C═C) 1390 y 1370 (d, CH₃ -Boc) . MS: 237 (100); 164 (88); 136 (38); 121 (25); 107 (27).

Ethyl (2S, E)-N-Boc-[(2,2-dimethyl)-4-cyclopentylidene]pyroglutamate

Oil. ¹ HNMR (CDCl₃) 0.93, 1.01 (2s, 6H, 2×CH₃), 1.23 (t, 3H, J=7.0 Hz, CH₃ CH₂), 1.43 (s, 9H, (CH₃)₃ C), 1.65, 2.17 (2m, 6H, CH₂ CH₂ CH₂), 3.11 (q, 2H, J=9.6 Hz, CHCH₂), 4.18 (t, 2H, J=7.0 Hz, CH₂ CH₃) and 4.5 ppm (dd, 1H, J=2.3, 9.6 Hz, CHCO₂ Et) . m/z 295 (M⁺ -56, 1%), 25 (M⁺ -100, 12), 222 (2), 178 (11), 157 (13), 95 (19), 57 (100) and 41 (19). IR (cm⁻¹): 3037 (C═C), 1792, 1747 and 1717 (C═O).

Ethyl (2S, Z)-N-Boc-[(2,2-dimethyl)-4-cyclopentylidene]pyroglutamate

Oil. ¹ HNMR (CDCl₃) 1.05, 1.09 (2s, 6H, 2×CH₃), 1.21 (t, 3H, J=7.2 Hz, CH₃ CH₂), 1.43 (s, 9H, (CH₃)₃ C), 1.39-1.70 (m, 5H), 2.6-3.2 (m, 3H), 4.15 (q, 2H, J=7.2 Hz, CH₂ CH₃) and 4.49 ppm (dd, 1H, J=3.8, 9.9 Hz, CHCO₂ Et). ¹³ CNMR (CDCl₃): 13.97 (CH₃ CH₂), 22.72, 26.35, 33.67 (CH₂ CH₂ CH₂), 24.85, 25.13 (2×CH₃), 27.76 ((CH₃)₃ C), 43.06 (CHCH₂), 44.60 ((CH₃)₂ C), 55.77 (CHCO₂ Et), 61.27 (CH₃ CH₂), 82.77 ((CH₃)₃ CO), 117.35, 150.16 (C═C), 167.10, 167.64 (2×O═CN) and 171.37 ppm (C═O). m/z 295 (M⁺ -56, 2%), 25 (M⁺ -100, 30), 222 (2), 178 (43), 95 (45), 82 (11), 57 (100) and 41 (39). IR (cm⁻¹): 1779, 1746 and 1717 (C═O).

Ethyl-(2S, E, E)-N-Boc-4-cinnamylidenepyroglutamate

M.p.: 80-81° C. [α]_(D) =+57.3 (c 1.06, CHCl₃). ¹ HMNR (CDCl₃): 7.49-7.23 (m, 6H, Ph and HC═), 6.95 (d, 1H, J=15.5 Hz, CH-Ph), 6.78 (dd, 1H, J=11.0 y 15.5 Hz, HC═), 4.68 (dd, 1H, J=10.1 and 3.6 Hz, H-2), 4.30-4.17 (m, 2H, CO₂ CH₂), 3.18 (ddd, 1H, J=18.1, 10.1 and 3.0 Hz), 2.84 (dt, 1H, J=18.1 and 3.0 Hz), 1.52 (s, 9H, C(CH₃)₃), 1.29 (t, 3H, J=7.1 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃): 170.5, 165.8, 149.0, 140.4, 135.4, 133.7, 128.5, 128.1 (2C), 127.3, 126.6 (2C), 122.5, 82.5, 60.9, 55.3, 27.2 (3C), 25.4, 13.5. IR (CHCl₃): 2995, 1780, 1735, 1310, 1150 cm⁻¹. HRMS calcd. for C₂₁ H₂₅ NO₅ : 371.1722 found 371.1732.

Ethyl-(2S, E, E)-N-Boc-4-(o-methoxycinnamylidene)pyroglutamate

EtOAc/hexane 1:4 [α]_(D) =+7.2 (c 1.0, CHCl₃). ¹ HNMR (CDCl₃): 7.52 (d, 1H, J=7.8 Hz), 7.32-7.22 (m, 3H), 6.95-6.72 (m, 3H), 4.59 (dd, 1H, J=10.4 and 4.1 Hz, H-2), 4.25 (q, 2H, J=7.1 Hz, CO₂ CH₂), 3.87 (s, 3H, OCH₃), 3.24-3.10 (m, 1H), 2.72 (dt, 1H, J=18.1 and 2.9 Hz), 1.52 (s, 9H, C(CH₃)3), 1.28 (t, 3H, J=7.1 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃): 171.2, 166.5, 157.3, 149.8, 136.5, 135.6, 130.6, 127.3, 126.7, 124.8, 123.5, 120.5, 110.9, 83.3, 61.6, 55.9, 55.4, 27.8 (3C), 26.0, 14.0. IR (film): 1790, 1770, 1755, 1747, 1371 cm⁻¹.

Ethyl-(2S, E, E)-N-Boc-4-(p-nitrocinnamylidene)pyroglutamate

EtOAc/hexane 1:3. M.p.: 162-163° C. [α]_(D) =+48.3 (c 0.6, CHCl₃). ¹ HNMR (CDCl₃): 8.22 and 7.61 (AA'BB', 4H), 7.32-7.24 (m, 1H), 6.97-6.93 (m, 2H), 4.72 (dd, 1H, J=10.0 and 3.0 Hz, H-2), 4.30-4.19 (m, 2H, CO₂ CH₂), 3.22 (ddd, 1H, J=18.1, 10.0 and 2.8 Hz), 2.89 (dt, 1H, J=18.1 and 2.8 Hz), 1.53 (s, 9H, C(CH₃)₃), 1.30 (t, 3H, J=7.1 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃): 170.9, 166.0, 149.6, 147.5, 142.2, 138.0, 132.2, 130.9, 127.6 (2C), 127.1, 124.1 (2C), 83.8, 61.9, 55.9, 27.8 (3C), 26.2, 14.1. IR (KBr): 1784, 1747, 1514, 1336, 1155 cm⁻¹.

Benzyl (2S, E, E)-N-Boc-4-(p-dimethylaminocinnamylidene)pyroglutamate

EtOAc/hexane 1:3. M.p.: 136-138° C. [α]_(D) =+175.1 (c 0.7, CHCl₃). ¹ HNMR (CDCl₃): 7.38-7.21 (m, 4H), 6.81 (d, 1H, J=15.3 Hz, HC═), 6.65 (d, 1H, J=11.6 Hz), 6.54 (dd, 1H, J=15.3 and 11.6 Hz), 5.19 (AB, 2H, CO₂ CH₂), 4.71 (dd, 1H, J=10.2 and 2.5 Hz, H-2), 3.22-3.04 (m, 1H), 3.01 (s, 6H, NMe₂), 2.79 (dt, 1H, J=17.7 and 2.7 Hz), 1.44 (s, 9H, C(CH₃)₃). ¹³ CNMR (CDCl₃): 171.1, 166.8, 150.9, 149.9, 142.2, 136.0, 135.0, 128.7 (2C), 128.6 (2C), 128.5 (2C), 128.4 (2C), 123.9, 116.4, 111.0, 83.2, 67.2, 55.9, 40.1 (2C), 27.7 (3C), 26.1. IR (KBr): 1770, 1601, 1321, 1280, 1149 cm⁻¹.

Benzyl (2S, E)-N-Boc-4-pentylidenepyroglutamate

EtOAc/hexane 1:5. [α]_(D) =-13.3 (c 0.3, CHCl₃). ¹ HNMR (CDCl₃): 7.32 (s, 5H), 6.69 (tt, 1H, J=7.7 and 2.7 Hz, HC═), 5.16 (AB, 2H, CO₂ CH₂), 4.63 (dd, 1H, J=10.2 and 3.5 Hz, H-2), 3.00-2.82 (m, 1H), 2.61-2.49 (m, 1H), 2.12-2.02 (m, 2H), 1.41 (s, 9H, C(CH₃)₃), 1.37-1.22 (m, 4H), 0.85 (t, 3H, J=7.0 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃): 171.0, 165.9, 149.8, 139.6, 135.0, 128.6 (2C), 128.5 (2C), 128.4, 128.1, 83.5, 67.2, 55.8, 30.2, 29.1, 27.7 (3C), 25.5, 22.3, 13.7. IR (KBr): 1786, 1746, 1717, 1317, 1155 cm⁻¹.

Ethyl (2S)-N-Boc-4-cyclobutylidenepyroglutamate

EtOAc/hexane 1:3. [α]_(D) =-5.0 (c 0.4, CHCl₃).¹ HNMR (CDCl₃): 4.55 (dd, 1H, J=10.3 and 3.7 Hz, H-2), 4.26-4.10 (m, 2H, CO₂ CH₂), 3.21-3.12 (m, 2H), 2.91-2.68 (m, 3H), 2.49-2.35 (m, 1H), 2.20-1.83 (m, 2H), 1.48 (s, 9H, C(CH₃)₃), 1.24 (t, 3H, J=7.1 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃): 171.5, 165.6, 158.9, 150.4, 118.6, 83.2, 61.5, 55.8, 32.4, 31.5, 27.9 (3C), 25.2, 18.3, 14.1. IR (KBr): 1782, 1743, 1715, 1319, 1153 cm⁻¹.

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-(2-methylpropylidene)pyroglutamate

A 85:15 mixture of E/Z isomers was obtained. The diastereomers were separated by chromatography (hexane/ethyl acetate 3:1). For the E isomer: Oil. ¹ HNMR (CDCl₃) d 7.30 (S, 5H), 6.50 (dt, 1H, HC═), 5.15 (AB, 2H, CO₂ CH₂), 4.60 (dd, 1H, H-2), 3.00-2.80 (m, 1H), 2.60-2.30 (m, 2H), 1.50 (s, 9H, C(CH₃)₃), 1.00 (d, 3H), 0.95 (d, 3H). ¹³ C NMR (CDCl₃) d 171.0, 166.4, 149.8, 145.8, 134.9, 126.6, 126.4, 125.9, 83.6, 67.2, 55.9, 29.0, 28.1, 27.7, 25.3, 21.6, 21.4

For the Z isomer: Oil. ¹ HNMR (CDCl₃) d 7.30 (S, 5H), 5.30 (dt, 1H, HC═), 5.2 (s, 2H, CO₂ CH₂), 3.17 (dd, 1H), 3.21 (m, 1H), 3.19 (m, 1H), 3.75 (m, 1H), 1.40 (s, 9H), 1.00 (d, 3H), 0.95 (d, 3H)

Benxyl (2S)-1-(tert-butoxycarbonyl)-4-(3-methylbutylidene)pyroglutamate

A 85:15 mixture of E/Z isomers was obtained. The diastereomers were separated by chromatography (hexane/ethyl acetate 3:1). For the E isomer: Oil. ¹ HNMR (CDCl₃) d 7.35 (s, 5H), 6.70 (m, 1H, HC═), 5.15 (AB, 2H, CO₂ CH₂), 4.60 (dd, 1H, H-2), 3.00-2.50 (m, 2H), 2.00-1.60 (m, 3H), 1.50 (S, 9H, C(CH₃)₃), 0.90 (d, 3H), 0.80 (d, 3H). ¹³ C NMR (CDCl₃) d 170.9, 165.8, 149.8, 138.4, 134.9, 128.8, 128.5, 128.4, 128.3, 83.3, 67.1, 55.7, 38.3, 27.9, 27.6, 25.6, 22.2.

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-(3-phenylpropylidene)pyroglutamate

A 85:15 mixture of E/Z isomers was obtained. The diastereomers were separated by chromatography (hexane/ethyl acetate 3:1). For the E isomer: Oil. ¹ HNMR (CDCl₃) d 7.35-7.10 (m, 10H), 6.70 (m, 1H, HC═), 5.15 (AB, 2H, CO₂ CH₂), 4.55 (dd, 1H, H-2), 2.80-2.30 (m, 4H), 140 (S, 9H, C(CH₃)₃). ¹³ C NMR (CDCl₃) d 170.4, 165.2, 149.2, 140.1, 137.6, 134.6, 128.7, 128.0, 125.4, 82.8, 66.6, 55.4, 33.6, 30.8, 26.1.

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-diethylmethylidene)pyroglutamate

Oil. ¹ HNMR (CDCl₃) d 7.3 (S, 5H), 5.20 (S, 2H, CO₂ CH₂), 4.55 (dd, 1H, H-2), 3.00-2.50 (m, 4H), 2.20-2.00 (m, 3H), 1.50 (S, 9H, C(CH₃)₃), 1.10-0.90 (m, 6H).

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-(2,2-dimethylpropylidene)pyroglutamate

Oil. 1HNMR (CDCl₃) d 7.35 (S, 5H), 6.60 (m, 1H), 5.20 (S, 2H, C₂ CH₂), 4.55 (dd, 1H, H-2), 3.20-2.65 (m, 2H), 1.50 (s, 9H, C(CH₃)₃). 1.10 (s, 9H).

Ethyl (2S, E)-1-(tert-butoxycarbonyl)-4-propylidenepyroglutamate

A 92:8 mixture of E/Z isomers was obtained. Isolation of the minor isomer was not possible. Pure E isomer was isolated by column chromatography (hexane/ethyl acetate 4:1). Oil. 70% yield [a]_(D) =-11.30° (c 0.76, CHCl₃). IR (CHCl₃) 3010, 1780, 1735, 1315, 1155 cm⁻¹.¹ HNMR (CDCl₃) d 6.71 (tt, J=2.9 and 7.5 Hz, 1H), 4.61 (dd, J=3.7 and 10.1 Hz, 1H), 4.22 (q, J=7.2 Hz, 2H), 3.04-2.88 (m, 1H), 2.66-2.53 (m, 1H), 2.23-2.07 (m, 2H), 1.51 (s, 9H), 1.28 (t, J=7.2 Hz, 3H), 1.06 (t, J=7.5 Hz, 3H). ¹³ C NMR (CDCl₃) d 171.2, 165.9, 149.9, 140.6, 127.8, 83.3, 61.5, 55.8, 27.8 (3C), 25.4, 22.7, 14.0, 12.5. HRMS calcd for C₁₀ H₁₅ NO₃ [M+-CO₂ C(CH₃)₃ +1]: 197.1052, found 197.1046.

Benzyl (2S, E)-N-Boc-4-pentylidenepyroglutamate

36% Yield. EtOAc/hexane 1:5. [α]_(D) =-13.3 (c 0.3, CHCl₃).¹ HNMR (CDCl₃) d 7.32 (s, 5H), 6.69 (tt, 1H, J=7.7 and 2.7 Hz, HC═), 5.16 (AB, 2H, CO₂ CH₂), 4.63 (dd, 1H, J=10.2 and 3.5 Hz, H-2), 3.00-2.82 (m, 1H), 2.61-2.49 (m, 1H), 2.12-2.02 (m, 2H), 1.41 (s, 9H, C(CH₃)₃), 1.37-1.22 (m, 4H), 0.85 (t, 3H, J=7.0 Hz, CH₂ CH₃). ¹³ CNMR (CDCl₃) d 171.0, 165.9, 149.8, 139.6, 135.0, 128.6 (2C), 128.5 (2C), 128.4, 128.1, 83.5, 67.2, 55.8, 30.2, 29.1, 27.7 (3C), 25.5, 22.3, 13.7. IR (KBr): 1786, 1746, 1717, 1317, 1155 cm⁻¹.

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-(2-methylpropylidene)pyroglutamate

A 85:15 mixture of E/Z isomers was obtained. The diastereomers were separated by chromatography (hexane/ethyl acetate 3:1). 70% yield. For the E isomer: Oil. ¹ HNMR (CDCl₃) d 7.30 (s, 5H), 6.50 (dt, 1H, HC═), 5.15 (AB, 2H, CO₂ CH₂), 4.60 (dd, 1H, H-2), 3.00-2.80 (m, 1H), 2.60-2.30 (m, 2H), 1.50 (s, 9H, C(CH₃)₃), 1.00 (d, 3H), 0.95 (d, 3H). ¹³ C NMR (CDCl₃) d 171.0, 166.4, 149.8, 145.8, 134.9, 126.6, 126.4, 125.9, 83.6, 67.2, 55.9, 29.0, 28.1, 27.7, 25.3, 21.6, 21.4.

For the Z isomer: Oil. ¹ HNMR (CDCl₃) d 7.30 (s, 5H), 5.30 (dt, 1H, HC═), 5.2 (s, 2H, CO₂ CH₂), 3.17 (dd, 1H), 3.21 (m, 1H), 3.19 (m, 1H), 3.75 (m, 1H), 1.40 (s, 9H), 1.00 (d, 3H) , 0.95 (d, 3H).

Benzyl(2S)-1-(tert-butoxycarbonyl)-4-(2,2-dimethylpropylidene)pyroglutamate

Oil. ¹ HNMR (CDCl₃) d 7.35 (s, 5H), 6.60 (m, 1H), 5.20 (s, 2H, CO₂ CH₂), 4.55 (dd, 1H, H-2), 3.20-2.65 (m, 2H), 1.50 (s, 9H, C(CH₃)₃), 1.10 (s, 9H).

Benzyl (2S, 4E, 6E)-N-Boc-(2-butadienylene) pyroglutamate: Oil; [α]D=+9.7 (c 2, CHCl3). 1H NMR (CHCl3) 7.24 (s, 5H), 6.80 (d, J=8.0 Hz, 1H), 6.00 (m, 2H), 5.05 (m, 2H), 4.58 (dd, J=3.5 and 10.3 Hz, 1H), 2.95 (m, 1H), 2.60 (m, 1H), 1.77 (d, J=6.0 Hz, 3H), 1.33 (s, 9H).13C NMR (CHCl3) 170.7, 166.4, 149.4, 140.2, 134.7, 134.5, 128.2, 128.1,127.9, 126.8, 126.5, 83.0, 66.9, 55.6, 27.4, 25.5, 18.7. IR (film) 3050,1780, 1750, 1650, 1300, 1150 cm-1.

Procedure B

General procedures for the hydrolysis of 4-substituted N-BOC pyroglutamate ethyl esters. Synthesis of γ-alkyl glutamic acid hydrochlorides:

To a solution of the title compounds (2 mmol) in THF (15 mL) was added a 2.5 N aqueous solution of LiOH (14.4 mL, 36 mmol). The mixture was stirred at room temperature for four hours, then acidified to pH 2 with 1N HCl solution and extracted with ethyl ether (3×20 mL). The combined organic layers were dried over Na₂ SO₄ and concentrated in vacuo to give an oily residue which was reacted with a saturated HCl solution in ethyl acetate for one hour at room temperature. The resulting white solid was triturated with ethyl ether (3×20 mL). The final amino acids were isolated either as hydrochlorides or as zwitterions by treatment of a methanolic solution of the hydrochloride with propylene oxide.

(2S, E)-4-Propylideneglutamic acid

[α]_(D) =+11° (c 0.5, 3N HCl). ¹ H NMR (D₂ O) d 6.88 (t, J=7.6 Hz, 1H), 3.67 (dd, J=6.1 and 7.7 Hz, 1H), 2.80-2.57 (m, 2H), 2.09 (quintet, J=7.6 Hz, 2H), 0.87 (t, J=7.6 Hz, 3H). ¹³ C NMR (D₂ O) d 182.8, 177.4, 141.0, 133.3, 57.4, 35.3, 22.8, 14.3.

(2S,E,E) -2-Amino-4-(p-nitrocinnamylidene)pentanedioic acid

M.p.: >200 C. [α]_(D) =+10.0 (c 0.1, 6N HCl).¹ HNMR (MeOH-d₄ /KOD):8.20 and 7.79 (AA'BB', 4H), 7.52 (dd, 1H, J=15.3 and 11.4 Hz, HC═), 7.22 (d, 1H, J=11.4 Hz, HC═), 6.87 (d, 1H, J=15.3 Hz, HC═), 3.40 (dd, 1H, J=8.1 and 4.6 Hz, H-2), 3.02 (dd, 1H J=12.8 and 4.6 Hz), 2.75 (dd, 1H, J=12.8 and 8.1 Hz). ¹³ CNMR (MeOH-d₄ /KOD): Decomposes in solution 183.3, 177.3, 147.6, 145.0, 138.6, 137.1, 136.0, 130.0, 128.6 (2C), 125.2 (2C), 57.3, 35.2. IR (KBr): 1649, 1608, 1531, 1344 cm⁻¹.

(2S,E,E)-2-Amino-4-(p-dimethylaminocinnamylidene)pentanedioic acid

M.p.: 195-196 C. [α]_(D) =+44.7 (c 0.4, 1N HCl).¹ HNMR (MeOH-d₄ /KOD): 7.40 and 6.74 (AA'BB', 4H), 7.25 (d, 1H, J=11.2 Hz, HC═), 7.00 (dd, 1H, J=15.1 and 11.2 Hz, HC═), 6.73 (d, 1H, J=15.1 Hz, HC═), 3.36 (dd, 1H, J=9.3 and 4.6 Hz, H-2), 2.92 (s, 6H, NMe₂), 2.96-2.88 (m, 1H), 2.63 (dd, 1H J=12.7 and 9.3 Hz). ¹³ CNMR (MeOH-d₄ /KOD): 183.1, 177.4, 152.1, 139.1, 138.8, 134.0, 129.2, 127.1, 127.7, 114.1, 57.7, 41.0. IR (KBr): 1668, 1597, 1358, 1159 cm⁻¹.

(2S,E,E)-2-Amino-4-cinnamylidenepentanedioic acid

M.p.: 198 C (dec). ¹ HNMR (D₂ O/KOD): 7.01-6.86 (m, 2H), 6.80-6.71 (m, 2H), 6.80-6.71 (m, 2H), 6.52 (m, 2H), 2.90 (dd, 1H, J=9.2 and 3.9 Hz, H-2), 2.44 (dd, 1H, J=12.8 and 3.9 Hz), 2.22 (dd, 1H J=12.8 and 9.2 Hz). ¹³ CNMR (D₂ O/MeOH-d₄ /KOD): 183.5, 177.8, 138.6, 138.1, 137.9, 135.8, 130.1 (2C), 129.6, 128.0 (2C), 125.8, 57.3, 34.9. IR (KBr): 1678, 1624, 1439, 1167 cm⁻¹.

(2S,E)-2-Amino-4-pentylidenepentanedioic acid

M.p.: 173-175 C. [α]_(D) =+37.0 (c 0.2, 1N HCl).¹ HNMR (MeOH-d₄ /KOD): 6.52 (t, 1H, J=7.4 Hz, HC═), 3.30 (m, 1H, H-2), 2.74 (dd, 1H, J=13.2 and 4.7 Hz), 2.44 (dd, 1H J=13.2 and 9.1 Hz), 2.18 (m, 2H), 1.36 (m, 4H), 0.88 (m, 3H). ¹³ CNMR (MeOH-d₄ /KOD): 182.8, 177.4, 139.5, 136.9, 57.4, 35.4, 32.7, 29.3, 23.5, 14.5. IR (KBr): 2957, 1713, 1688, 1636 cm⁻¹.

(2S)-2-Amino-4-cyclobutylidenepentanedioic acid

M.p.: 212-214 C. [α]_(D) =+5.0 (c 0.2, 1N HCl).¹ HNMR (MeOH-d₄ /KOD): 3.27 (dd, 1H, J=8.9 and 4.2 Hz, H-2), 3.00 (q, 2H, J=7.2 Hz), 2.77 (t, 2H, J=7.6 Hz), 2.59 (dd, 1H, J=13.2 and 4.2 Hz), 2.20 (dd, 1H J=13.2 and 8.9 Hz), 1.93 (quintuplet, 2H, J=7.6 Hz). ¹³ CNMR (MeOH-d₄ /KOD): 183.0, 176.9, 152.2, 128.8, 57.2, 36.8, 34.0, 31.7, 17.7. IR (KBr): 2915, 1663, 1632, 1595, 1308 cm⁻¹.

(2S,E)-2-Amino-4-(p-chlorophenylmethylidene)pentanedioic acid

M.p.: 215 C (dec). [α]_(D) =+32.9 (c 0.1, 1N HCl).¹ HNMR (MeOH-d₄ /KOD): 7.36 (AA'BB', 4H), 3.43 (dd, 1H, J=8.6 and 5.6 Hz, H-2), 2.93 (dd, 1H, J=13.4 and 5.6 Hz), 2.68 (dd, 1H, J=13.4 and 8.6 Hz). ¹³ CNMR (MeOH-d₄ /KOD): 183.5, 177.2, 140.6, 137.2, 134.4, 134.0, 131.9 (2C), 129.5 (2C), 57.3, 36.0. IR (KBr): 1697, 1651, 1493, 1093 cm⁻¹.

(2S)-2-Amino-4-cyclohexylidenepentanedioic acid

Mixture of regioisomers (2:1).¹ HNMR (MeOH-d₄ /KOD): 5.58 (bs, 1H, HC═), 3.24 (dd, 1H, J=10.2 and 3.5 Hz, H-2), 3.15 (dd, 1H, J=9.0 and 4.3 Hz), 2.92 (dd, 1H, J=9.7 and 4.5 Hz), 2.72 (dd, 1H, J=13.8 and 3.5 Hz), 2.42 (dd, 1H, J=13.8 and 10.2 Hz), 2.20 (m, 5H), 2.02 (m, 2H), 1.55 (m, 10H). ¹³ CNMR (MeOH-d₄ /KOD): 185.5, 182.7, 182.4, 180.8, 139.3, 137.6, 131.3, 122.9, 57.2, 56.8, 55.5, 39.0, 37.2, 34.2, 30.8, 29.3, 29.1, 27.9, 26.4, 24.2, 23.6. IR (KBr): 2955, 1686, 1339 cm⁻¹.

(2S,E)-2-Amino-4-cyclopentylmethylidenepentanedioic acid

M.p.: 173-175 C. [α]_(D) =+23.0 (c 0.1, 1N HCl).¹ HNMR (MeOH-d₄ /KOD): 6.45 (d, 1H, J=10.0 Hz, HC═), 3.28 (m, 1H, H-2), 2.83 (m, 1H), 2.78 (dd, 1H, J=13.4 and 4.8 Hz), 2.45 (dd, 1H, J=13.4 and 9.3 Hz), 1.87-1.58 (m, 6H), 1.37-1.22 (m, 2H). ¹³ CNMR (MeOH-d₄ /KOD): 182.7, 177.5, 144.6, 135.2, 57.5, 40.4, 35.6, 34.6 (2C), 26.6 (2C). IR (KBr): 2928, 1705, 1658, 1604, 1400 cm⁻¹.

(2S)-2-Amino-4-isopropylidenepentanedioic acid

M.p.: 198-199° C. [α]_(D) =+24.5 (c 0.2, 1N HCl). ¹ H NMR (MeOH-d₄ /KOD) 3.26 (dd, 1H, J=9.6 and 3.8 Hz, H-2), 2.54 (dd, 1H, J=13.7 and 3.8 Hz), 2.43 (dd, 1H J=13.7 and 9.6 Hz), 1.80 (s, 3H, CH₃), 1.70 (s, 3H, CH³). ¹³ C NMR (MeOH-d₄ /KOD) 182.7, 180.7, 134.3, 130.4, 57.2, 38.1, 23.1, 20.2. IR (KBr) 1717, 1657, 1605, 1408, 1202 cm⁻¹.

(2S)-2-Amino-4-carboxy-5-ethylhept-4-enoic acid

¹ H NMR (MeOH-KOD) 3.00 (m, 1H), 2.45 (m, 1H), 2,20-1,70 (m, 5H), 0.70 (m, 6H). ¹³ C NMR (MeOH-KOD) 182.7, 180.6, 140.5, 134.1, 57.0, 37.8, 27.4, 23.9, 14.0, 13.7.

(2S,4E)-2-Amino-4-carboxy-7-phenylhept-4-enoic acid

[α]_(D) =+3.1 (c 0.35, Py). ¹ H NMR (D₂ O-Pyr-d⁵) 6.9-6.55 (m, 5H), 6.20 (m, 1H), 3.00 (m, 1H), 2.40-1.85 (m, 6H). ¹³ C NMR (D₂ O-Pyr-d⁵) 175.7, 173.7, 141.3, 141.2, 132.4, 128.2, 128.1, 125.6, 54.4, 33.9, 29.6, 28.7. Anal. (C₁₄ H₁₇ NO₄.H₂ O) C, H, N.

(2S,4E)-2-Amino-4-carboxy-5-(2-methylthio)ethylpent-4-enoic acid

[α]_(D) =+28.0 (c 1, 1N HCl). ¹ H NMR (D₂ O-Pyr-d⁵) 7.04 (t, J=5.7 Hz, 1H), 4.21 (dd, J=3.7 and 8.5 Hz, 1H), 3.28 and 3.11 (part AB of an ABX system, JAB=14.7 Hz, JAX=3.7 Hz and JBX=8.5 Hz), 2.84 (m, 4H), 2.37 (s, 3H). ¹³ C NMR (D₂ O-Pyr-d⁵) 178.1, 176.3, 142.7, 135.7, 57.0, 34.7, 31.5, 29.8, 16.5. IR (KBr) 3447, 1671, 1593, 1533, 1402, 1262 cm⁻¹. Anal. (C₉ H₁₅ NO₄ S.H₂ O) C, H, N.

(2S,4E)-2-Amino-4-carboxy-5-propylpent-4-enoic acid

[α]_(D) =+36.3 (c 1, 1N HCl). ¹ H NMR (D₂ O-Pyr-d⁵) 7.07 (t, J=6.5 Hz, 1H), 4.17 (dd, J=3.6 and 8.9 Hz, 1H), 3.26 and 3.06 (part AB of an ABX system, JAB=14.7 Hz, JAX=3.6 Hz and JBX=8.9 Hz), 2.48 (c, J=7.3 Hz, 2H), 1.69 (m, 2H) , 1.18 (t, J=7.2 Hz,3H) .¹³ C NMR (D₂ O-Pyr-d⁵) 178.6, 176.6, 145.8, 134.1, 57.2, 32.4, 31.5, 24.1, 15.6. IR (KBr) 3400, 1699, 1589, 1526, 1350, 1219 cm⁻¹. Anal. (C₉ H₁₅ NO₄.H₂ O) C, H, N.

(2S,4E)-2-Amino-4-carboxy-6-methylhept-4-enoic acid

Mp>200° C.; [α]_(D) =-22.0 (c 0.2 , Py). ¹ H NMR (D₂ O-Pyr-ds) 6.50 (d, J=10.3 Hz, 1H), 3.75 (dd, J=3.7 and 8.5 Hz, 1H), 3.85 (part A of an ABX system, JAB=14.7 Hz, JAX=3.7 Hz, 1H), 2.72-2.50 (m, 2H), 0.90 (m, 6H) .¹³ C NMR (D₂ O-Pyr-d⁵) 176.5, 173.9, 149.5, 129.5, 54.9, 29.0, 27.2, 21.5. IR (KBr) 3450, 1686, 1636, 1263 cm⁻¹. Anal. (C₉ H₁₅ NO₄.H₂ O) C, H, N.

(2S,4Z)-2-Amino-4-carboxy-6-methylhept-4-enoic acid

[α]_(D) =+52.0 (c 0. 5, Py). ¹ H NMR (MeOD-KOD) 5.15 (d, J=9.1 Hz, 1H), 3.40-3.25 (m, 1H), 3.00-2.70 (m, 2H), 3.00-2.75 (m, 2H), 2.16 (m, 1H), 1.00 (m, 6H). ¹³ C NMR (D₂ O-Pyr-d⁵) 177.3, 173.6, 141.5, 131.0, 54.5, 35.6, 28.3, 22.0, 21.8. Anal. (C₉ H₁₅ NO₄.^(1/2) H₂ O) C, H, N.

(2S)-2-Amino-4-carboxy-5-ethylhept-4-enoic acid

[α]_(D) =30.0 (c 0.2, Py). ¹ H NMR (MeOH-d⁴ -KOD) 6.45 (s, 1H), 3.25 (m, 1H), 2.85 (dd, J=5.7 and 13.7 Hz, 1H), 2.48 (dd, J=9 and 13.7 Hz, 1H), 1.12 (s, 9H) ¹³ C NMR (MeOH-d⁴⁻ KOD) 182.7, 178.7, 147.0, 136.8, 57.4, 35.9, 33.7, 31.8. Anal. (C₁₀ H₁₇ NO4.H₂ O) C, H, N.

(2S,4E)-2-Amino-4-carboxy-7-methyloct-4-enoic acid

Mp 190-199° C. [α]_(D) =+14.0 (C 0.5, Py). ¹ H NMR (D₂ O-Pyr-d⁵) 6.53 (m, 1H), 3.57 (m, 1H), 2.72 (m, 1H), 2.48 (m, 1H), 1.85 (m, 2H), 1.40 (m, 1H), 0.60 (m, 6H). ¹³ C NMR (D₂ O-Pyr-d⁵) 176.0, 173.9, 142.1, 132.0, 54.6, 36.6, 28.9, 27.6, 21.5, 21.4. Anal. (C₁₀ H₁₇ NO₄.H₂ O) C, H, N.

(2S, E)-2-amino-4-(4,4-diphenylbutylidene)pentanedioic acid, hydrochloride

75% Yield. White solid, m.p. 155-7° C. (dec) . [α]_(D) =+17.0 (c 0.5, DMSO). ¹ H NMR (MeOH-d⁴) 7.40-7.00 (m, 10H), 3.94 (m, 1H), 3.85 (dd, J=6.3 and 7.6 Hz, 1H), 2.77 and 2.61 (part AB of ABX system, J_(AB) =14.3 Hz, J_(AX) =6.3 Hz, J_(BX) =7.6 Hz, 2H), 2.40-2.10 (m, 4H). ¹³ C NMR (MeOH-d⁴) 171.4, 170.5, 148.5, 145.8, 129.6, 128.9, 127.8, 127.3, 53.7, 52.1, 35.3, 29.1, 28.4. IR (KBr pellet) 3428, 3300-2200 (CO₂ H), 1690, 1219 cm⁻¹.

(2S, Z)-2-amino-4-(4,4-diphenylbutylidene)pentanedioic acid, hydrochloride

70% Yield. White solid, m.p. 196-8° C. (dec). [α]_(D=+) 46.0 (c 0.5, DMSO). ¹ H NMR (D₂ O/KOD/MeOH-d⁴) 7.45-7.15 (m, 10H), 5.39 (m, 1H), 3.99 (m, 1H), 3.23 (dd, J=3.5 and 10.0 Hz , 1H), 2.76 (dd, J=3.5 and 13.9 Hz, 1H), 2.32-2.00 (m, 5H). ¹³ C NMR (D₂ O/KOD/MeOH-d⁴) 183.1, 179.2, 146.5, 146.4, 137.9, 131.6, 129.7, 128.9, 128.8, 127.3, 56.0, 51.4, 42.6, 35.8, 28.8. IR (KBr pellet) 3430, 3300-2200 (CO₂ H), 1699, 1630, 1252 cm⁻¹.

(2S)-2-Amino-4-cyclobutylidenepentanedioic acid

M.p.: 212-214° C. [α]_(D) =+5.0 (c 0.2, 1N HCl) .¹ H NMR (MeOH-d₄ /KOD) 3.27 (dd, 1H, J=8.9 and 4.2 Hz, H-2), 3.00 (q, 2H, J=7.2 Hz), 2.77 (t, 2H, J=7.6 Hz), 2.59 (dd, 1H, J=13.2 and 4.2 Hz), 2.20 (dd, 1H J=13.2 and 8.9 Hz), 1.93 (quintuplet, 2H, J=7.6 Hz). ¹³ C NMR (MeOH-d₄ /KOD) 183.0, 176.9, 152.2, 128.8, 57.2, 36.8, 34.0, 31.7, 17.7. IR (KBr) 2915, 1663, 1632, 1595, 1308 cm⁻¹. Anal. (C₉ H₁₃ NO₄.^(1/2) H₂ O) C, H, N.

(2S)-2-Amino-4-cyclopentylidenepentanedioic acid

M.p.: 205° C. [α]_(D) =-22.0 (c 0.5 , DMSO). ¹ H NMR (D₂ O-Pyr-d⁵) 4.22 (dd, J=3.5 and 10.6 Hz, 1H), 3.32 (dd, J=3.6 and 14.0 Hz, 1H), 3.10-2.60 (m, 5H), 2.0-1.65 (m, 4H). ¹³ CNMR (D₂ O-Pyr-d⁵) 179.40, 176.6, 157.4, 126.0, 56.7, 35.5, 35.4, 33.8, 28.6, 27.6. IR (KBr) 3410, 3090, 1713, 1660, 1624, 1410, 1178 cm⁻¹. Anal. (C₁₀ H₁₅ NO₄.2H₂ O) C, H, N.

(2S,E)-2-Amino-4-[(2,2-dimethyl)cyclopentylidene]pentanedioic acid hydrochloride

¹ H NMR (MeOH-d⁴ -KOD) 4.04 (m, 1H), 3.44 (m, 1H), 2.56 (m, 1H), 2.40-2.10 (m, 4H), 1.81 (m, 2H), 1.12 (s, 6H).¹³ C NMR (MeOH-d⁴⁻ KOD) 179.1, 173.2, 148.9, 128.8, 52.9, 47.6, 41.5, 41.2, 34.2, 30.1, 27.4, 27.1. IR (KBr) 3400, 1760, 1750, 1625, 1230 cm¹⁻.

(2S,Z)-2-Amino-4-[(2,2-dimethyl)cyclopentylidene]pentanedioic acid hydrochloride

¹ H NMR (MeOH-d⁴ -KOD) 4.13 (m, 1H), 3.22 (m, 1H), 3.05 (m, 1H), 2.81 (m, 2H), 1.69 (m, 4H), 1.30 (s, 3H), 1.27 (s, 3H). ¹³ C NMR (MeOH-d⁴⁻ KOD) 171.15 (2C), 119.6, 111.9, 54.1, 45.9, 45.2, 37.9, 31.4, 27.9 (2C), 23.8. IR 1733, 1717 cm⁻¹.

(2S,4E)-2-Amino-4-carboxy-5-cyclopropylpent-4-enoic acid

Mp 204° C. [α]hd D=+32.9 (c 1 , 1N HCl). ¹ H NMR (D₂ O-Pyr-d⁵) 6.50 (d, J=10.0 Hz, 1H), 4.30 (dd, J=4.0 and 9.1 Hz, 1H), 3.46 and 3.18 (part AB of an ABX system, JAB=14.8 Hz, JAX=4.0 Hz and JBX=9.1 Hz), 2.05 (m, 1H), 1.24 (m, 2H), 0.9 (m, 2H). 13C NMR (D₂ O-Pyr-d⁵) 178.0, 176.5, 151.1, 131.2, 57.4, 31.7, 13.4, 10.5. IR (KBr) 3420, 1721, 1657, 1632, 1412, 1123 cm⁻¹. Anal. (C₉ H₁₃ NO₄.H₂ O) C, H, N.

(2S,E)-2-Amino-4-cyclopentylmethylidenepentanedioic acid

M.p.: 173-175° C. [α]_(D) =+23.0 (c 0.1, 1N HCl).¹ H NMR (MeOH-d₄ /KOD) 6.45 (d, 1H, J=10.0 Hz, HC═), 3.28 (m, 1H, H-2), 2.83 (m, 1H), 2.78 (dd, 1H, J=13.4 and 4.8 Hz), 2.45 (dd, 1H, J=13.4 and 9.3 Hz), 1.87-1.58 (m, 6H), 1.37-1.22 (m, 2H). ¹³ C NMR (MeOH-d₄ /KOD) 182.7, 177.5, 144.6, 135.2, 57.5, 40.4, 35.6, 34.6 (2C), 26.6 (2C). IR (KBr) 2928, 1705, 1658, 1604, 1400 cm⁻¹. Anal. (C₁₁ H₁₇ NO₄.H₂ O) C, H, N.

(2S,4E)-2-Amino-4-carboxy-5-cyclohexylpent-4-enoic acid

M.p.: 205° C. [α]_(D) =+32.0 (c 1, 1N HCl). ¹ H NMR (D₂ O-Pyr-d⁵) 6.92 (d, J=10.3 Hz, 1H) 4.25 (m, 1H), 3.40 (m, 1H), 3.12 (m, 1H), 2.73 (m, 1H) 2.0-1.15 (m, 10H). ¹³ C NMR (D₂ O-Pyr-d⁵) 178.4, 176.2, 150.4, 132.0, 57.5, 39.1, 34.1, 34.0, 31.6, 27.6, 27.2, 27.0. IR (KBr) 3500, 1688, 1584, 1496, 1300 cm⁻¹. Anal. (C₁₂ H₁₉ NO₄.H₂ O) C, H, N.

(2S,4E,6E)-2-Amino-4-carboxyocta-4,6-dienoic acid

M.p.: 190° C. [α]_(D) =+37.0 (c 0.5, DMSO). ¹ H NMR (D₂ O-Pyr-d⁵) 7.46 (d, J=11.2 Hz, 1H), 6.78 (m, 1H), 6.42 (dq, J=6.8 and 14.4 Hz, 1H), 4.15 (dd, J=3.6 and 9.0 Hz, 1H), 3.33 and 3.11 (part AB of an ABX system, JAB=14.4 Hz, JAX=3.6 Hz and JBX=9.0 Hz, 2H), 2.14 (d, J=6.8 Hz, 3H). ¹³ C NMR (D₂ O-Pyr-d⁵) 178.8, 176.4, 141.7, 141.2, 130.8, 128.8, 57.1, 31.5, 20.4. IR (KBr) 3426, 3034, 1684, 1641, 1242 cm⁻¹.

(2S,E)-2-Amino-4-anthrylidenepentanedioic acid

M.p.: 167-269 C. [α]_(D) =+55.7 (c 0.35, DMSO).¹ H NMR (MeOH-d₄ /KOD) 8.35-8.29 (m, 1H), 8.11-7.98 (m, 4H), 7.52-7.41 (m, 4H), 3.34 (dd, 1H, J=10.6 and 2.3 Hz, H-2), 2.84 (dd, 1H, J=13.2 and 2.3 Hz), 1.96 (dd, 1H, J=13.2 and 10.6 Hz). ¹³ C NMR (MeOH-d₄ /KOD) 187.8, 176.2, 144.1, 133.0, 132.8, 132.6, 131.1, 130.1, 129.9, 129.8, 127.3, 127.0, 126.9, 126.8, 126.4, 126.3, 56.5, 38.3. IR (KBr) 3435, 1678, 1622, 1238 cm⁻¹. Anal. (C₂₀ H₁₆ NO₄.2H₂ O) C, H, N.

(2S, E, E) -2-Amino-4-(2-methoxycinnamylidene)pentanedioic acid

M.p.: 187-189° C. [α]_(D) =+37.0 (c 0.1, 3N HCl) .¹ H NMR (MeOH-d₄ /KOD) 7.17 (d, 1H, J=7.6 Hz), 6.84 (t, 1H, J=7.8 Hz), 6.71-6.68 (m, 3H), 6.58-6.50 (m, 2H), 3.78 (s, 3H, OCH₃), 2.84 (dd, 1H, J=9.5 and 4.8 Hz, H-2), 2.38 (dd, 1H J=13.3 and 4.8 Hz), 2.15 (dd, 1H, J=13.3 and 9.5 Hz). ¹³ C NMR (MeOH- d₄ /KOD) 183.5, 177.7, 157.7, 138.8, 135.5, 133.0, 131.1, 128.1, 126.7, 126.6, 122.4, 113.1, 57.4, 56.9, 35.1. IR (KBr) 1674, 1595, 1489, 1246 cm⁻¹. Anal. (C₁₅ H₁₇ NO₅.H₂ O) C, H, N.

EXAMPLE 2

A tablet is prepared using the ingredients below:

    ______________________________________                                         Quantity                                                                       (mg/tablet)                                                                    ______________________________________                                         Active Ingredient      250                                                     Cellulose, microcrystalline                                                                           400                                                     Silicon dioxide, fumed  10                                                     Stearic acid            5                                                      Total                  665    mg                                               ______________________________________                                    

The components are blended and compressed to form tablets each weighing 665 mg.

EXAMPLE 3

Tablets each containing 60 mg of active ingredient are made as follows:

    ______________________________________                                         Active Ingredient  60 mg                                                       Starch             45 mg                                                       Microcrystalline cellulose                                                                        35 mg                                                       Polyvinylpyrrolidone                                                                               4 mg                                                       Sodium carboxymethyl starch                                                                       4.5 mg                                                      Magnesium stearate 0.5 mg                                                      Talc                1 mg                                                       Total              150 mg                                                      ______________________________________                                    

The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

EXAMPLE 4

Capsules each containing 80 mg medicament are made as follows:

    ______________________________________                                         Active Ingredient  80 mg                                                       Starch             59 mg                                                       Microcrystalline cellulose                                                                        59 mg                                                       Magnesium stearate  2 mg                                                       Total              200 mg                                                      ______________________________________                                    

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 sieve, and filled into hard gelatin capsules in 200 mg quantities.

EXAMPLE 5

Suspensions each containing 50 mg of medicament per 5 ml dose are made as follows:

    ______________________________________                                         Active Ingredient     50 mg                                                    Sodium carboxymethyl cellulose                                                                       50 mg                                                    Syrup               1.25 ml                                                    Benzoic acid solution                                                                              0.10 ml                                                    Flavor              q.v.                                                       Color               q.v.                                                       Purified water to total                                                                              5 ml                                                     ______________________________________                                    

The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume. 

We claim:
 1. A compound of the formula: ##STR6## in which n is 1 or 2, R¹ is --CO₂ H, R₂ is hydrogen or C₁₋₄ alkyl andR³ is hydrogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₄ alkyl, optionally substituted phenyl C₂₋₁₀ alkenyl,(optionally substituted phenyl)₂ -C₁₋₄ alkyl, optionally substituted C₃₋₇ cycloalkyl, optionally substituted C₃₋₇ cycloalkyl-C₁₋₄ alkyl or optionally substituted C₃₋₇ cycloalkyl-C₂₋₁₀ alkenyl, or R² and R³, together with the carbon atom to which they are attached, form an optionally substituted C₄₋₇ cycloalkyl group; or a salt or ester thereof other than the compounds γ-propylidene-L-glutamic acid, γ-ethylidene-L-glutamic acid and γ-methylidene-L-glutamic acid.
 2. A compound according to claim 1 in which n is
 1. 3. A compound according to claim 1 which has 2S stereochemistry.
 4. A compound according to claim 1 in which n is 1, R¹ is --CO₂ H, R² is hydrogen and R³ is C₁₋₄ alkyl.
 5. A compound according to claim 1 wherein R³ is C₃ or C₄ alkyl.
 6. A compound according to claim 1 in which n is 1, R¹ is --CO₂ H, R² is hydrogen and R³ is C₃₋₄ alkyl or branched alkyls such as isopropyl or R² and R³ together with the carbon atom to which they are attached form an optionally substituted C₄ or C₅ cycloalkyl.
 7. A compound according to claim 1 in which R² is hydrogen and R³ is C₁₋₄ alkyl.
 8. A compound selected from(2S, E, E) -2-Amino-4-(p-nitrocinnamylidene)pentanedioic acid, (2S, E, E) -2-Amino-4-(p-dimethylaminocinnamylidene)pentanedioic acid, (2S, E, E) -2-Amino-4-cinnamylidenepentanedioic acid, (2S, E)-2-Amino-4-pentylidenepentanedioic acid, (2S) -2-Amino-4-isopropylidenepentanedioic acid, (2S)-2-Amino-4-cyclobutylidenepentanedioic acid, (2S, E) -2-Amino-4-(p-chlorophenylmethylidene)pentanedioic acid, (2S)-2-Amino-4-cyclohexylidenepentanedioic acid (2S, E) -2-Amino-4-cyclopentylmethylidenepentanedioic acid and (2S)-2-Amino-4-cyclopentylidenedioic acid.
 9. A pharmaceutical formulation comprising a compound according to claim 1, or a pharmaceutically-acceptable salt or ester thereof, together with a pharmaceutically-acceptable diluent or carrier.
 10. A process for the production of compounds of formula (1) which comprises hydrolysing a compound of the formula: ##STR7## where R⁴ and R⁵ are each carboxy protecting groups, to give a compound of formula (I).
 11. A compound according to claim 1, or a pharmaceutically-acceptable salt or ester thereof, for use as a pharmaceutical.
 12. A method of treating an animal suffering from or susceptible to a disorder of the central nervous system, which comprises administering a compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof.
 13. A method according to claim 12, in which the animal is a human. 